Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kymera Therapeutics Inc (NQ: KYMR ) 48.69 -0.78 (-1.58%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 243,186 Open 49.84 Bid (Size) 47.65 (1) Ask (Size) 70.00 (3) Prev. Close 49.47 Today's Range 48.33 - 50.60 52wk Range 9.600 - 53.27 Shares Outstanding 55,307,775 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News The Analyst Landscape: 7 Takes On Kymera Therapeutics Today 9:00 EDT Via Benzinga Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics September 09, 2024 Via Benzinga Performance YTD +92.07% +92.07% 1 Month -0.51% -0.51% 3 Month +61.12% +61.12% 6 Month +21.12% +21.12% 1 Year +230.10% +230.10% More News Read More This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday August 26, 2024 Via Benzinga Unveiling 6 Analyst Insights On Kymera Therapeutics August 12, 2024 Via Benzinga Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update August 07, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 July 31, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Why Kymera Therapeutics Stock Is Soaring Today July 09, 2024 Via The Motley Fool XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details July 14, 2024 Via Benzinga Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 09, 2024 Via Benzinga Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday July 09, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics June 17, 2024 Via Benzinga Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews May 24, 2024 Via Benzinga Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day July 09, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy July 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 Via FinancialNewsMedia Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 From FN Media Group LLC Via GlobeNewswire Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting June 14, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting June 01, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming June Investor Conferences May 29, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting May 23, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting May 22, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting May 14, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming May Investor Conferences May 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 02, 2024 Via InvestorPlace Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update May 02, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.